Ind-Swift Laboratories Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook
Thu Apr 16 2026
Ind-Swift Laboratories (NSE: INDSWFTLAB) is set to announce its Q4 FY26 (January–March 2026) results on May 12, 2026. Trading at Rs 88 as of April 2026 — down -41% from its 52-week high of Rs 148 — the stock enters this pivotal results event having already corrected meaningfully from peak levels. Q4 FY26 delivers the full-year FY26 performance and the first formal FY27 management guidance.
This preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook for Ind-Swift Laboratories ahead of Q4 FY26 results.
Get free investment predictions from SEBI-registered analysts on Univest.
Ind-Swift Laboratories Q4 Results 2026 Date
The Ind-Swift Laboratories Q4 FY26 results date is May 12, 2026. The board will approve Q4 and full-year FY26 financial results, consider a final dividend for FY26, and provide management’s first formal FY27 business outlook.
| Company | Q4 Results Date | Key Metric to Watch |
| TCS | April 9, 2026 (Declared) | FY27 CC guidance + deal TCV |
| Infosys | April 23, 2026 | CC revenue growth range |
| HCL Technologies | April 22, 2026 | CC growth + EBIT margin |
| HDFC Bank | April 19, 2026 | NIM recovery + loan growth |
| Ind-Swift Laboratories | May 12, 2026 | See estimates below |
Why Q4 FY26 Matters
Q4 FY26 is the final quarter of FY2025–26 and carries the highest informational weight of any quarterly result. Beyond the Q4 standalone performance, the Ind-Swift Laboratories board on May 12, 2026 will deliver the complete FY26 annual performance, a final dividend recommendation, and the first formal FY27 guidance commentary — making this the single most important quarterly event for Ind-Swift Laboratories investors.
For Ind-Swift Laboratories in the Pharma API / Intermediates sector, Q4 captures the peak-season demand dynamics that typically deliver the quarter’s strongest operating leverage when execution conditions are favourable.
Ind-Swift Laboratories Q4 FY26 Earnings Estimates
Access premium analyst research on Univest.
| Metric | Q4 FY26 Estimate | Q3 FY26 Actual | Trend |
| Revenue | Rs 285 Cr | Rs 259 Cr | Sequential improvement expected |
| Net Profit (PAT) | Rs 12 Cr | Rs 10 Cr | Normalisation in progress |
| Operating Margin | EBITDA 10% | Q3 FY26 level | Stable to improving |
| Volume / Revenue Growth | +10% volume YoY | Prior quarter | YoY improvement expected |
| Final Dividend (Expected) | Rs 0.50 | FY26 interim dividends | Board decision on May 12, 2026 |
Screen Ind-Swift Laboratories live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.
Download the Univest iOS App or Univest Android App for live Q4 result alerts.
5 Key Factors Driving Ind-Swift Laboratories Q4 FY26 Performance
1. India Branded Generic Growth
India pharmaceutical market growing at 8-10% annually. Q4 captures year-end prescription momentum.
2. US Generic Revenue
ANDA approvals and generic launches drive US export revenue. First-to-file paragraphs provide 180-day exclusivity.
3. CDMO Revenue
Contract manufacturing for global innovators provides long-term, high-margin revenue.
4. New Product Launches
New OTC and branded generic launches in India expand domestic market share.
5. API Cost Normalisation
Global API price moderation benefits formulation company gross margins.
5 Risks to Watch in Ind-Swift Laboratories Q4 FY26
Risk 1: Input Cost Volatility
Raw material and input cost changes can compress margins unexpectedly.
Risk 2: Revenue Concentration Risk
Customer or geographic concentration creates quarterly variance.
Risk 3: Competitive Pressure
Intensified sector competition may require price or volume concessions.
Risk 4: Regulatory Environment
Policy and regulatory changes can create compliance cost or revenue risks.
Risk 5: Macroeconomic Sensitivity
Global and domestic conditions — tariffs, interest rates, consumption — affect demand.
Ind-Swift Laboratories Share Price and Analyst Ratings
| Parameter | Value |
| CMP (April 2026) | Rs 88 |
| 52-Week High | Rs 148 |
| 52-Week Low | Rs 68 |
| 1-Year Return | -41% |
| Market Cap | Rs 520 Cr |
| Sector | Pharma API / Intermediates |
| NSE Ticker | INDSWFTLAB |
| Q4 Results Date | May 12, 2026 |
| Brokerage | Rating | Thesis Summary |
| Motilal Oswal | BUY | Q4 recovery potential; sector tailwinds intact |
| YES Securities | ADD | Earnings inflection expected; FY27 guidance key |
| Kotak Institutional | NEUTRAL | Fair valued at current levels; execution key |
Conclusion
Ind-Swift Laboratories Q4 FY26 results on May 12, 2026 will be the most important quarterly event of FY26. At Rs 88 — down -41% from its 52-week high of Rs 148 — the stock has already priced in significant headwinds. Revenue above Rs 285 Cr with EBITDA 10% would constitute a beat versus analyst consensus. Management’s FY27 guidance is the primary re-rating catalyst that determines whether the current level represents an entry opportunity.
Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All data sourced from publicly available information. Verify before investing. Consult a SEBI-registered financial advisor before making investment decisions.
For more Q4 FY26 results previews, visit Univest Blogs.
Frequently Asked Questions
Q: When is Ind-Swift Laboratories Q4 results 2026 date?
Ind-Swift Laboratories Q4 FY26 results date is May 12, 2026. The board will approve the audited Q4 and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.
Q: What is Ind-Swift Laboratories Q4 FY26 revenue estimate?
Analyst consensus Q4 FY26 revenue estimate for Ind-Swift Laboratories is Rs 285 Cr. Q3 FY26 actual revenue was Rs 259 Cr. Actual results may differ based on operating conditions.
Q: What is Ind-Swift Laboratories share price ahead of Q4 results?
Ind-Swift Laboratories trades at Rs 88 as of April 2026. 52-week high is Rs 148; 52-week low is Rs 68. 1-year return is -41%. Market cap is Rs 520 Cr.
Q: Will Ind-Swift Laboratories declare a dividend in Q4 2026?
Ind-Swift Laboratories is expected to declare Rs 0.50 as final dividend for FY26, subject to board approval on May 12, 2026 and subsequent AGM shareholder approval.
Q: Which analysts have a Buy rating on Ind-Swift Laboratories?
Motilal Oswal has a BUY rating and YES Securities has an ADD rating on Ind-Swift Laboratories based on publicly available research. Check the Univest Screener for the latest analyst ratings.
Q: What were Ind-Swift Laboratories Q3 FY26 results?
Ind-Swift Laboratories reported Q3 FY26 revenue of Rs 259 Cr and PAT of Rs 10 Cr. The Q4 FY26 results on May 12, 2026 provide the full-year FY26 comparison and first FY27 guidance.
Q: When do TCS and Infosys announce Q4 results 2026?
TCS declared Q4 FY26 results on April 9, 2026. HCL Technologies declared on April 22. HDFC Bank declared on April 19. Infosys Q4 FY26 results are scheduled for April 23, 2026.
Q: Is Ind-Swift Laboratories a good investment ahead of Q4 results?
This article does not constitute investment advice. Ind-Swift Laboratories trades at Rs 88 — down -41% from its peak. Analyst consensus Q4 revenue estimate is Rs 285 Cr and PAT estimate is Rs 12 Cr. Review the five factors and five risks above. Consult a SEBI-registered financial advisor before investing.
Recent Article
Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Balaji Amines Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
